Effective January 2, 2024, Harrow, Inc. appointed John P. Saharek as the President and Chief Executive Officer of the Company?s ImprimisRx division, in addition to his current role as Chief Commercial Officer of the Company. Mr. Saharek will continue to report to Mark L. Baum, Chief Executive Officer and Chairman of the Company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
10.53 USD | +5.30% | +0.77% | -5.98% |
Apr. 11 | Craig-Hallum Starts Harrow With Buy Rating, $24 Price Target | MT |
Mar. 22 | B. Riley Securities Adjusts Harrow Health's Price Target to $26 From $30, Maintains Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.98% | 372M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- HROW Stock
- News Harrow, Inc.
- Harrow, Inc. Appoints John P. Saharek as President and Chief Executive Officer of its ImprimisRx Division